Logo
x

Search

Subscribe Now

SC

Biogen's Tysabri (natalizumab- SC) Receives EC's Marketing Authorization to Treat Relapsing-Remitting Multiple Sclerosis

Biogen's Tysabri (natalizumab- SC) Receives EC's Marketing Authorization to Treat Relapsing-Remitting Multiple Sclerosis

  • April 8, 2021
Janssen's Darzalex (daratumumab- SC) Receives Health Canada Approval for the Treatment of Patients with Multiple Myeloma

Janssen's Darzalex (daratumumab- SC) Receives Health Canada Approval for the Treatment of Patients with Multiple Myeloma

  • August 4, 2020
Roche Reports Results of Fixed-Dose SC Combination of Perjeta (pertuzumab) and Herceptin (trastuzumab) in P-III FeDeriCa Study for HER2-Positive Breast Cancer

Roche Reports Results of Fixed-Dose SC Combination of Perjeta (pertuzumab) and Herceptin (trastuzumab) in P-III FeDeriCa Study for...

  • December 12, 2019
Roche Reports Results of Perjeta (pertuzumab) Fixed Dose SC Combination Therapy in P-III FeDeriCa Study for HER2+ve Breast Cancer

Roche Reports Results of Perjeta (pertuzumab) Fixed Dose SC Combination Therapy in P-III FeDeriCa Study for HER2+ve Breast Cancer

  • September 13, 2019
Grifols' Xembify (20% SC Immunoglobulin) Receives FDA's Approval for the Treatment of Primary Immunodeficiencies

Grifols' Xembify (20% SC Immunoglobulin) Receives FDA's Approval for the Treatment of Primary Immunodeficiencies

  • July 5, 2019
Takeda Reports FDA's Acceptance of BLA for Entyvio (Vedolizumab SC) as a Maintenance Therapy in Moderate to Severe Active Ulcerative Colitis

Takeda Reports FDA's Acceptance of BLA for Entyvio (Vedolizumab SC) as a Maintenance Therapy in Moderate to Severe Active Ulcerati...

  • May 10, 2019
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.